Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Cerebrospinal Fluid Research|June 29, 2005
Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implicationsHela-Felicitas Petereit, Dirk ReskeExpert Review of Clinical Immunology|May 19, 2010
Use of rituximab in multiple sclerosis: current progress and future perspectivesDirk Reske, Walter F HauptNeuroimmunomodulation|July 18, 2009
Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donorsDirk Reske, Anne V Thomas, Hela-Felicitas Petereit, et al.Journal of Neurology|June 18, 2010
Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosisHela-Felicitas Petereit, Dirk Reske, Hayrettin Tumani, et al.Biomolecules|April 3, 2021
Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular MarkersOliver Neuhaus, Wolfgang Köhler, Florian Then Bergh, et al.Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|May 27, 2026
Support factors and barriers in the implementation of an app for refugees in an inpatient psychiatric setting: a qualitative interview studyThea Kreyenschulte, Dirk Reske, Jürgen Zielasek, et al.BMC Health Services Research|December 14, 2023
Blended-ALMAMAR app for inpatient mental health care for refugees: study protocol for a multicenter implementation study within the I-REACH consortium (Internet based REfugee mentAl healtH Care)Isabelle Reinhardt, Laura Schmidt, Dirk Reske, et al.Schizophrenia Research|July 10, 2024
Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-studyViktoria Galuba, Joachim Cordes, Sandra Feyerabend, et al.The Lancet. Psychiatry|March 11, 2022
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trialChristian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, et al.European Archives of Psychiatry and Clinical Neuroscience|September 6, 2019
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and designChristian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, et al.Pageof 1